Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Tandem Diabetes Care, Inc. or AdaptHealth Corp. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Tandem Diabetes Care, Inc. and AdaptHealth Corp. compare based on key financial metrics to determine which better meets your investment needs.

About Tandem Diabetes Care, Inc. and AdaptHealth Corp.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services; and medical devices, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; and other HME devices and supplies. It also provides PAP machines, wheelchairs, hospital beds, oxygen concentrators, ventilators, insulin pumps, diabetes management and wound care supplies, orthopedic bracing, breast pumps and supplies, walkers, commodes, enteral supplies, and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. was founded in 2012 and is headquartered in Conshohocken, Pennsylvania.

Latest Health Care Equipment & Supplies and Tandem Diabetes Care, Inc., AdaptHealth Corp. Stock News

As of September 9, 2026, Tandem Diabetes Care, Inc. had a $1.3 billion market capitalization, compared to the Health Care Equipment & Supplies median of $408.9 million. Tandem Diabetes Care, Inc.’s stock is down 13.5% in 2026, down 7.5% in the previous five trading days and up 52.88% in the past year.

Currently, Tandem Diabetes Care, Inc. does not have a price-earnings ratio. Tandem Diabetes Care, Inc.’s trailing 12-month revenue is $1.0 billion with a -6.1% net profit margin. Year-over-year quarterly sales growth most recently was 5.8%. Analysts expect adjusted earnings to reach $-0.667 per share for the current fiscal year. Tandem Diabetes Care, Inc. does not currently pay a dividend.

As of September 9, 2026, AdaptHealth Corp. had a $760.4 million market cap, putting it in the 41st percentile of all stocks. AdaptHealth Corp.’s stock is down 42.1% in 2026, down 4.6% in the previous five trading days and down 39.49% in the past year.

Currently, AdaptHealth Corp. does not have a price-earnings ratio. AdaptHealth Corp.’s trailing 12-month revenue is $3.4 billion with a -6.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.7%. Analysts expect adjusted earnings to reach $-0.454 per share for the current fiscal year. AdaptHealth Corp. does not currently pay a dividend.

How We Compare Tandem Diabetes Care, Inc. and AdaptHealth Corp. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Tandem Diabetes Care, Inc. and AdaptHealth Corp.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Tandem Diabetes Care, Inc. and AdaptHealth Corp. Stock Value Grades

Company	Ticker	Value
Tandem Diabetes Care, Inc.	TNDM	D
AdaptHealth Corp.	AHCO	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Tandem Diabetes Care, Inc. has a Value Score of 26, which is Expensive. AdaptHealth Corp. has a Value Score of 83, which is Deep Value.

The Value Stock Winner: AdaptHealth Corp.

As you can clearly see from the Value Grade breakdown above, AdaptHealth Corp. is considered to have better value than Tandem Diabetes Care, Inc.. For investors who focus solely on a company’s valuation, AdaptHealth Corp. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Tandem Diabetes Care, Inc. and AdaptHealth Corp. Growth Grades

Company	Ticker	Growth
Tandem Diabetes Care, Inc.	TNDM	C
AdaptHealth Corp.	AHCO	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Tandem Diabetes Care, Inc. has a Growth Score of 45, which is Average. AdaptHealth Corp. has a Growth Score of 59, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Tandem Diabetes Care, Inc. or AdaptHealth Corp. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Tandem Diabetes Care, Inc. or AdaptHealth Corp. is the better investment when it comes to sustainable growth.

Tandem Diabetes Care, Inc. and AdaptHealth Corp.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Tandem Diabetes Care, Inc.	TNDM	B
AdaptHealth Corp.	AHCO	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Tandem Diabetes Care, Inc. has a Earnings Estimate Score of 63, which is Positive. AdaptHealth Corp. has a Earnings Estimate Score of 11, which is Very Negative.

The Earnings Estimate Revisions Grade Winner: Tandem Diabetes Care, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Tandem Diabetes Care, Inc. has a better Earnings Estimate Revisions Grade than AdaptHealth Corp.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Tandem Diabetes Care, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Tandem Diabetes Care, Inc. and AdaptHealth Corp. Grades

In addition to Estimate Revisions, Growth and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Tandem Diabetes Care, Inc. and AdaptHealth Corp. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Tandem Diabetes Care, Inc. or AdaptHealth Corp. Stock?

Overall, Tandem Diabetes Care, Inc. stock has a Value Score of 26, Growth Score of 45 and Estimate Revisions Score of 63.

AdaptHealth Corp. stock has a Value Score of 83, Growth Score of 59 and Estimate Revisions Score of 11.

Comparing Tandem Diabetes Care, Inc. and AdaptHealth Corp.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.